


DR3 Ligand Antibody / TNFRSF25 Ligand / VEGI [clone VEGI/13117] (V6048)


Catalog No.	Formulation	Size
V6048-100UG	0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide	100 ug
V6048-20UG	0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide	20 ug
V6048SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

[Bulk quote request](#)


Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG2b, kappa
Clone Name	VEGI/13117
UniProt	O95150
Localization	Membrane, Secreted
Applications	Immunohistochemistry (FFPE) : 1-2ug/ml
Limitations	This DR3 Ligand/TNFRSF25 Ligand antibody is available for research use only.



DR3 Ligand Antibody Placenta IHC. Immunohistochemistry of DR3 Ligand antibody in human placenta tissue. FFPE human placenta shows strong membranous and cytoplasmic HRP-DAB brown staining within trophoblastic epithelial cells lining chorionic villi, consistent with TNFRSF25 ligand / TNFSF15 expression in placental and endothelial-associated compartments. Clone VEGI/13117 was used as a monoclonal antibody for detection. An inset image shows PBS substituted for the primary antibody as a negative control, demonstrating absence of specific staining. Heat-induced epitope retrieval was performed by heating sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 minutes at 95°C followed by cooling at room temperature for 20 minutes prior to staining.



DR3 Ligand Antibody Testis IHC. Immunohistochemistry of DR3 Ligand antibody in human testis tissue. FFPE human testis demonstrates cytoplasmic and membranous HRP-DAB brown staining within seminiferous tubule epithelial cells, including spermatogenic cells at varying stages of maturation, consistent with TNFRSF25 ligand / TNFSF15 expression in immune-regulatory and paracrine signaling contexts. Clone VEGI/13117 was used as a monoclonal antibody for detection. An inset image shows PBS substituted for the primary antibody as a negative control, confirming absence of specific staining. Heat-induced epitope retrieval was performed by heating sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 minutes at 95°C followed by cooling at room temperature for 20 minutes prior to staining.



SDS-PAGE Analysis of Purified DR3 Ligand/TNFRSF25 Ligand antibody (VEGI/13117). Confirmation of Purity and Integrity of Antibody.

Description

DR3 Ligand antibody recognizes Tumor necrosis factor ligand superfamily member 15, also known as TNFSF15, VEGI, and TL1A, a cytokine that functions as the cognate ligand for Death Receptor 3, encoded by the TNFRSF25 gene. As the TNFRSF25 ligand, this protein plays a central role in immune regulation and inflammatory signaling. DR3 Ligand Antibody is developed to detect endogenous TNFSF15 in research applications focused on receptor-ligand biology and T cell activation pathways.

TNFRSF25, commonly referred to as DR3, is a member of the tumor necrosis factor receptor superfamily expressed on T lymphocytes and other immune cell populations. Binding of its ligand triggers downstream signaling cascades involving NF- κ B activation and apoptosis-related pathways. Through this interaction, the TNFRSF25 ligand regulates T helper cell expansion, cytokine production, and adaptive immune responses. Dysregulated signaling in this pathway has been implicated in autoimmune disease, chronic inflammation, and immune-mediated tissue injury.

The gene encoding DR3 Ligand, TNFSF15, is located on chromosome 9q32 and produces a type II transmembrane protein that can be proteolytically cleaved to generate a soluble cytokine form. Expression has been documented in endothelial cells, antigen-presenting cells, and inflamed tissues. In addition to immune activation, the protein historically described as Vascular endothelial growth inhibitor exhibits anti-angiogenic properties, linking receptor-mediated immune signaling with vascular remodeling processes.

Altered TNFSF15 expression has been associated with inflammatory bowel disease, rheumatoid arthritis, and tumor-associated immune modulation. In oncologic contexts, VEGI has been investigated for its ability to influence tumor angiogenesis and immune microenvironment dynamics. These dual immune and vascular functions make DR3 Ligand a critical mediator at the interface of inflammation and endothelial biology.

Clone VEGI/13117 is a monoclonal antibody that recognizes the TNFRSF25 ligand and supports studies of DR3-mediated signaling, cytokine regulation, and immune pathway modulation in diverse experimental systems.

For additional TL1A / TNFSF15 / VEGI research antibodies targeting inflammatory cytokine signaling and TNF superfamily immune pathways, explore the broader [TL1A Antibody](#) page featuring recombinant rabbit monoclonal clone rVEGI/1283.

Application Notes

Optimal dilution of the DR3 Ligand/TNFRSF25 Ligand antibody should be determined by the researcher.

Immunogen

A recombinant fragment (around amino acids 100-251) of human VEGI protein (exact sequence is proprietary) was used as the immunogen for the DR3 Ligand/TNFRSF25 Ligand antibody.

Storage

DR3 Ligand/TNFRSF25 Ligand antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.